Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Other Working Capital Changes (2023 - 2025)

Historic Other Working Capital Changes for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$4.0 million.

  • Compass Therapeutics' Other Working Capital Changes fell 15433.27% to -$4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.3 million, marking a year-over-year decrease of 24928.25%. This contributed to the annual value of $4.9 million for FY2024, which is 17182.79% up from last year.
  • According to the latest figures from Q3 2025, Compass Therapeutics' Other Working Capital Changes is -$4.0 million, which was down 15433.27% from -$6.3 million recorded in Q2 2025.
  • In the past 5 years, Compass Therapeutics' Other Working Capital Changes ranged from a high of $5.5 million in Q1 2025 and a low of -$6.3 million during Q2 2025
  • Moreover, its 3-year median value for Other Working Capital Changes was -$1.4 million (2023), whereas its average is -$609909.1.
  • Over the last 5 years, Compass Therapeutics' Other Working Capital Changes had its largest YoY gain of 48557.69% in 2025, and its largest YoY loss of 22621.4% in 2025.
  • Compass Therapeutics' Other Working Capital Changes (Quarter) stood at -$1.5 million in 2023, then skyrocketed by 136.89% to $539000.0 in 2024, then plummeted by 846.01% to -$4.0 million in 2025.
  • Its Other Working Capital Changes stands at -$4.0 million for Q3 2025, versus -$6.3 million for Q2 2025 and $5.5 million for Q1 2025.